Recent FDA discussions surrounding plausible mechanism and confirmatory evidence frameworks reflect this broader shift. Increasingly, translational success may depend not only on demonstrating that a therapy produced a measurable effect, but also on confirming how that effect emerged within intact biological systems. FDA guidance and recent regulatory discussions increasingly reference mechanistic, pharmacodynamic, and target engagement evidence as important components of confirmatory evidence frameworks.
As spatial biology moves closer to regulated translational and clinical development environments, the challenge is no longer simply generating more molecular data. The next phase of the field will depend on the ability to generate biologically coherent, reproducible, scalable, and clinically actionable mechanistic evidence.
Download the white paper to learn how spatial biology can support the FDA’s Evolving Confirmatory Evidence Framework.